The Long Shadow of Socioeconomic Deprivation over the Modern Management of Acute Myeloid Leukemia: Time to Unravel the Challenges

Overview

Journal Blood Cancer J

Date 2021 Aug 7

PMID 34362874

Citations 2

Authors

M Joseph John

Philip Kuriakose

Mark Smith

Eve Roman

Sudhir Tauro

Affiliations

Soon will be listed here.

Abstract

Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude standard therapy in many settings, with "real world" patients under-represented in clinical trials and prognostic models. Here, using a case-based format, we illustrate the impact that socioeconomic and anthropogeographical constraints can have on optimally managing AML in 4 different healthcare systems. The granular details provided, emphasize the need for the development and targeting of socioeconomic interventions that are commensurate with the changing landscape of AML therapeutics, in order to avoid worsening the disparity in outcomes between patients with biologically similar disease.

Citing Articles

Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia.

Prajapati S, Kumari N, Bhowmik D, Gupta R Ann Hematol. 2024; 103(11):4375-4400.

PMID: 39198271 DOI: 10.1007/s00277-024-05963-x.

Quantitative cost‑effectiveness index of cancer treatments.

Wu Z, Yang Y, Chen D Med Int (Lond). 2023; 3(2):17.

PMID: 37021300 PMC: 10068029. DOI: 10.3892/mi.2023.77.

References

Greene G, Fone D, Farewell D, Rodgers S, Paranjothy S, Carter B . Improving mental health through neighbourhood regeneration: the role of cohesion, belonging, quality and disorder. Eur J Public Health. 2019; 30(5):964-966. PMC: 7536250. DOI: 10.1093/eurpub/ckz221. View

Grimwade D, Ivey A, Huntly B . Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2015; 127(1):29-41. PMC: 4705608. DOI: 10.1182/blood-2015-07-604496. View

Rego E, Kim H, Ruiz-Arguelles G, Undurraga M, Uriarte M, Jacomo R . Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013; 121(11):1935-43. DOI: 10.1182/blood-2012-08-449918. View

Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C . The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98(5):1312-20. DOI: 10.1182/blood.v98.5.1312. View

Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D . Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2018; 104(1):113-119. PMC: 6312010. DOI: 10.3324/haematol.2018.188888. View

Lachowiez C, Loghavi S, Kadia T, Daver N, Borthakur G, Pemmaraju N . Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020; 4(7):1311-1320. PMC: 7160266. DOI: 10.1182/bloodadvances.2019001267. View

Hourigan C, Gale R, Gormley N, Ossenkoppele G, Walter R . Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017; 31(7):1482-1490. DOI: 10.1038/leu.2017.113. View

Tiong I, Dillon R, Ivey A, Teh T, Nguyen P, Cummings N . Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol. 2020; 192(6):1026-1030. PMC: 8048658. DOI: 10.1111/bjh.16722. View

Leighl N, Nirmalakumar S, Ezeife D, Gyawali B . An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. Am Soc Clin Oncol Educ Book. 2021; 41:1-12. DOI: 10.1200/EDBK_100028. View

10.

Rai K, HOLLAND J, Glidewell O, Weinberg V, Brunner K, Obrecht J . Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981; 58(6):1203-12. View

11.

Gopishetty S, Kota V, Guddati A . Age and race distribution in patients in phase III oncology clinical trials. Am J Transl Res. 2020; 12(9):5977-5983. PMC: 7540092. View

12.

Knaul F, Atun R, Farmer P, Frenk J . Seizing the opportunity to close the cancer divide. Lancet. 2013; 381(9885):2238-9. DOI: 10.1016/S0140-6736(13)60176-2. View

13.

Crombie I, Irvine L, Williams B, Sniehotta F, Petrie D, Jones C . Texting to Reduce Alcohol Misuse (TRAM): main findings from a randomized controlled trial of a text message intervention to reduce binge drinking among disadvantaged men. Addiction. 2018; . DOI: 10.1111/add.14229. View

14.

Munro A . Keynote comment: Deprivation and survival in patients with cancer: we know so much, but do so little. Lancet Oncol. 2005; 6(12):912-3. DOI: 10.1016/S1470-2045(05)70436-8. View

15.

Sekeres M, Peterson B, Dodge R, Mayer R, Moore J, Lee E . Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004; 103(11):4036-42. DOI: 10.1182/blood-2003-09-3118. View

16.

Paschka P, Marcucci G, Ruppert A, Mrozek K, Chen H, Kittles R . Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006; 24(24):3904-11. DOI: 10.1200/JCO.2006.06.9500. View

17.

Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A . Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016; 374(5):422-33. DOI: 10.1056/NEJMoa1507471. View

18.

Korula A, Abraham A, Abubacker F, Viswabandya A, Lakshmi K, Abraham O . Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country. Mycoses. 2017; 60(10):686-691. DOI: 10.1111/myc.12646. View

19.

Burnett A, Hills R, Milligan D, Kjeldsen L, Kell J, Russell N . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2010; 29(4):369-77. DOI: 10.1200/JCO.2010.31.4310. View

20.

Jabo B, Morgan J, Martinez M, Ghamsary M, Wieduwilt M . Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients. PLoS One. 2017; 12(4):e0174760. PMC: 5383052. DOI: 10.1371/journal.pone.0174760. View